Comparing Ocugen (NASDAQ:OCGN) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF)

Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) and Ocugen (NASDAQ:OCGN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Analyst Ratings

This is a summary of current ratings and price targets for Quantum Genomics Société Anonyme and Ocugen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Genomics Société Anonyme	0	0	0	0	N/A
Ocugen	0	0	3	0	3.00

Ocugen has a consensus target price of $5.33, indicating a potential upside of 428.05%. Given Ocugen’s higher possible upside, analysts plainly believe Ocugen is more favorable than Quantum Genomics Société Anonyme.

Earnings and Valuation

This table compares Quantum Genomics Société Anonyme and Ocugen”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Genomics Société Anonyme	N/A	N/A	N/A	N/A	N/A
Ocugen	$6.04 million	48.14	-$63.08 million	($0.19)	-5.32

Quantum Genomics Société Anonyme has higher earnings, but lower revenue than Ocugen.

Profitability

This table compares Quantum Genomics Société Anonyme and Ocugen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quantum Genomics Société Anonyme	N/A	N/A	N/A
Ocugen	N/A	-139.20%	-87.85%

Institutional and Insider Ownership

10.3% of Ocugen shares are owned by institutional investors. 4.3% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Quantum Genomics Société Anonyme has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.7, suggesting that its stock price is 270% more volatile than the S&P 500.

Summary

Ocugen beats Quantum Genomics Société Anonyme on 6 of the 8 factors compared between the two stocks.

About Quantum Genomics Société Anonyme

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.

About Ocugen

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.